BioViva Secures US Patent for Dual-Gene Therapy Targeting Age-Related Diseases

BioViva USA Inc., a biotechnology company focused on developing therapies for age-related diseases, has announced a significant milestone in its research efforts. The company has been granted U.S. Patent No. 12,653,907, titled "Methods of Treating or Preventing Age-Related Disorders." This patent covers a novel therapeutic approach that combines two key components: human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST).

Understanding the Components of the Therapy

Human Telomerase Reverse Transcriptase (hTERT)

Human telomerase reverse transcriptase (hTERT) is an enzyme that plays a crucial role in maintaining telomere length, which is vital for cellular longevity. Telomeres are protective caps at the ends of chromosomes that shorten as cells divide. When telomeres become too short, cells can no longer divide and enter a state known as senescence, which is associated with aging and age-related diseases. By utilizing hTERT, BioViva aims to extend the lifespan of cells, potentially delaying the onset of various age-related disorders.

Follistatin-344 (FST)

Follistatin-344 (FST) is a protein that inhibits myostatin, a negative regulator of muscle growth. By blocking myostatin, FST can promote muscle growth and regeneration. This is particularly relevant as muscle mass and strength tend to decline with age, leading to frailty and increased risk of falls and injuries in older adults. The combination of hTERT and FST could therefore not only help in maintaining cellular health but also in enhancing physical strength and resilience as individuals age.

The Significance of the Patent

The issuance of this patent by the United States Patent and Trademark Office on June 16, 2026, represents a critical step for BioViva in its mission to develop effective therapies for age-related conditions. The patent grants the company exclusive rights to this dual-gene therapy, potentially positioning it as a leader in the burgeoning field of genetic interventions for aging.

Implications for Longevity Enthusiasts

For individuals interested in longevity and health optimization, this development is particularly noteworthy for several reasons:

1. New Therapeutic Options: The patent could pave the way for innovative treatments targeting age-related diseases, which are a significant concern for those focused on extending healthspan.

2. Enhanced Cellular Regeneration: By combining hTERT and FST, the therapy may enhance cellular regeneration and muscle growth, contributing to improved overall health and vitality in aging populations.

3. Growing Interest in Genetic Therapies: The successful patenting of this dual-gene therapy underscores the increasing focus on genetic therapies as viable strategies for combating the effects of aging, which may inspire further research and investment in this area.

Future Directions and Considerations

While the patent is a promising development, it is essential to consider the next steps in bringing this therapy to clinical application. The transition from patent to practical treatment involves rigorous testing and regulatory approval, which can take several years. As BioViva continues to develop this therapy, the scientific community and longevity enthusiasts will be watching closely for updates on its efficacy and safety.

In conclusion, BioViva's recent patent acquisition for a dual-gene therapy targeting age-related diseases marks a significant advancement in the field of biotechnology and longevity research. By combining hTERT and FST, the company aims to address some of the most pressing challenges associated with aging, potentially offering new hope for healthier aging and improved quality of life for many individuals.